Search Results
GLOW: Assessing ibrutinib plus venetoclax in CLL
MRD outcomes from GLOW: venetoclax and ibrutinib in CLL
AE-free PFS benefit with first-line ibrutinib plus venetoclax for CLL: 64-month follow-up of GLOW
First-line ibrutinib and venetoclax in CLL
Fixed-duration ibrutinib and venetoclax for first-line CLL
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
Phase III GLOW trial: Ibrutinib plus venetoclax in previously untreated CLL/SLL
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukaemia
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL
CAPTIVATE: fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL
GLOW Trial Demonstrates Favourable Outcome for Elderly CLL Patients Compared to Chemotherapy
